Four-channel asymmetric Real-Time PCR hybridization probe assay: A rapid pre-screening method for critical BCR-ABL kinase domain mutations

Clinical Biochemistry

Volumn 45, Issue 4-5, 2012, Pages 345-351

  Martinez Serra, Jordi ^a   Gutiérrez, Antonio ^a   Marcús, Toni F ^a   Soverini, Simona ^b   Amat, Juan Carlos ^a   Navarro Palou, María ^a   Ros, Teresa ^a   Bex, Teresa ^a   Ballester, Carmen ^a   Bauça, Josep Miquel ^a   SanFelix, Sara ^a   Novo, Andrés ^a   Vidal, Carmen ^c   Santos, Carmen ^c   Besalduch, Joan ^a  

^a HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c UNIVERSITAT DE LES ILLES BALEARS   (Spain)

Author keywords

Asymmetric; BCR ABL; Dasatinib; FRET; Imatinib; Kinase; Nilotinib; PCR; Ponatinib; Real Time

Indexed keywords

BCR ABL PROTEIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; FEMALE; FLUORESCENCE RESONANCE ENERGY TRANSFER; GENE MUTATION; HUMAN; MALE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SCREENING TEST;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BASE SEQUENCE; BONE MARROW; DNA MUTATIONAL ANALYSIS; DNA PROBES; DRUG RESISTANCE, NEOPLASM; FEMALE; FLUORESCENCE RESONANCE ENERGY TRANSFER; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; MULTIPLEX POLYMERASE CHAIN REACTION; MUTATION; NUCLEIC ACID DENATURATION; PIPERAZINES; PYRIMIDINES; REAL-TIME POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDIES;

EID: 84857659296     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2011.12.026     Document Type: Article

References (15)

1. Zeidan A., Wang E.S., Wetzler M. What is Imatinib-resistant chronic myeloid leukemia? Identifying and managing loss of response. Clin Adv Hematol Oncol 2008, 6:673-683.
2. Branford S., Rudzki Z., Walsh S., Parkinson I., Grigg A., Szer J., et al. Detection of BCR-ABL mutations in patients with CML treated with Imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (p-loop) are associated with a poor prognosis. Blood 2003, 102:276-283.
3. Muller M.C., Lahaye T., Hochhaus A. Resistance to tumor specific therapy with Imatinib by clonal selection of mutated cells. Dtsch Med Wochenschr 2002, 127:2205-2207.
4. Soverini S., Hochhaus A., Nicolini F.E., Gruber F., Lange T., Saglio G., et al. BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood 2011, 118:1208-1215.
5. Lee T.S., Potts S.J., Kantarjian H., Cortes J., Giles F., Albitar M. Molecular basis explanation for Imatinib resistance of BCR-ABL due to T315I and p-loop mutations from molecular dynamics simulations. Cancer 2008, 112:1744-1753.
6. O'Hare T., Deininger M.W., Eide C.A., Clackson T., Druker B.J. Targeting the BCR-ABL signaling pathway in therapy-resistant Philadelphia chromosome-positive leukemia. Clin Cancer Res 2011, 17:212-221.
7. O'Hare T., Shakespeare W.C., Zhu X., Eide C.A., Rivera V.M., Wang F., et al. AP24534, a Pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell 2009, 16:401-412.
8. Barratt K., Mackay J.F. Improving real-time PCR genotyping assays by asymmetric amplification. J Clin Microbiol 2002, 40:1571-1572.
9. Martinez-Serra J., Gutierrez A., Amat J.C., Galmes B., Vila A., Julia M., et al. Rapid triplex asymmetric real-time PCR hybridization probe assay for the joint genotyping of F2, F5 and F12. Clin Biochem 2009, 42:1317-1324.
10. Martinez-Serra J., Maffiotte E., Gutierrez A., Duran M.A., Amat J.C., Besalduch J. New real-time PCR-based method for the joint genotyping of JAK2 (V617F) with inherited thrombophilic F5 and F2 mutations. Clin Chim Acta 2009, 410:59-63.
11. Sutton B.C., Allen R.A., Zhao Z.J., Dunn S.T. Detection of the JAK2V617F mutation by asymmetric PCR and melt curve analysis. Cancer Biomark 2007, 3:315-324.
12. Szilvasi A., Andrikovics H., Kalmar L., Bors A., Tordai A. Asymmetric PCR increases efficiency of melting peak analysis on the LightCycler. Clin Biochem 2005, 38:727-730.
13. Litzow M.R. Imatinib resistance: obstacles and opportunities. Arch Pathol Lab Med 2006, 130:669-679.
14. Polakova K.M., Lopotova T., Klamova H., Moravcova J. High-resolution melt curve analysis: initial screening for mutations in BCR-ABL kinase domain. Leuk Res 2008, 32:1236-1243.
15. Soverini S., Martinelli G., Amabile M., Poerio A., Bianchini M., Rosti G., et al. Denaturing-HPLC-based assay for detection of ABL mutations in chronic myeloid leukemia patients resistant to Imatinib. Clin Chem 2004, 50:1205-1213.